Healthcare
Abivax S.A.(AAVXF)
Live Price
Offline$101.25
+0.00% today
1Y Change
+1290.80%
Window
Jun 23, 2025 โ Jun 15, 2026
- Market Cap
- $7.94B
- Revenue Growth
- -100.0%
- EPS Growth
- -72.5%
- Dividend Yield
- 0.0%
Coverage: 247 bars ยท Jun 23, 2025 โ Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Abivax S.A. (AAVXF) is a Healthcare stock with a market cap of $7.94B and listed on OTC. The stock last traded around $101.25 and up 1290.8% across the available one-year price window (Jun 23, 2025 โ Jun 15, 2026). Baseline metrics include revenue growth of -100.0%, EPS growth of -72.5%, a dividend yield of 0.0%. What stands out right now is revenue -100.0%, EPS -72.5%, free cash flow -4.8% with operating margin 0.0% and ROIC -48.0%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines AAVXF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-100.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report landed above expectations
2026 was reported on May 22, 2026 with an EPS surprise of +24.0% and a revenue surprise of +278.9%.
The operating picture looks softer than before
Revenue is at -100.0% and EPS is at -72.5%, with operating margin around 0.0%.
The next real check-in already has a date
The next earnings event is scheduled for Sep 14, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged 0.0% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 22, 2026 | +24.0% | +0.0% | +0.0% | โ |
2026 Mar 23, 2026 | +9.5% | +0.0% | +0.0% | +0.0% |
2025 Dec 15, 2025 | -135.2% | +0.0% | +0.0% | +1.7% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
AAVXF
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
AAVXF Max Drawdown
-46.42%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for AAVXF and SPY.
Company Overview
Abivax S.A.
Other OTC
ABIVAX Sociรฉtรฉ Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV. It also develops ABX 196, an immune enhancer candidate that is in Phase 1/2 clinical trials for the treatment of hepatocellular cancer. In addition, the company engages in the research programs for the treatment of Dengue fever, influenza, and respiratory syncytial virus. ABIVAX Sociรฉtรฉ Anonyme has license contracts with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. The company was incorporated in 2013 and is headquartered in Paris, France.
- Leadership
- Marc de Garidel
- IPO Date
- Sep 27, 2016
- Employees
- 69
- Street Address
- 5, rue de la Baume
- Mailing
- Paris, 75008
- Region
- Paris, FR
- Reporting Currency
- USD
- Investor Line
- 33 1 53 83 08 41
- Last Updated
- May 6, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- 15.3
Growth
- Revenue
- -100.0%
- EPS
- -72.5%
- Free Cash Flow
- -4.8%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -165.2%
- ROIC
- -48.0%
Balance Sheet
- Debt/Equity
- 0.07
- Current Ratio
- 8.75
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.